What are hypocomplementemic urticarial vasculitis (HUV) and systemic lupus erythematosus (SLE)?

Hypocomplementemic Urticarial Vasculitis (HUV) and Systemic Lupus Erythematosus (SLE)

HUV is a rare small-vessel vasculitis characterized by persistent urticarial lesions (lasting >24 hours, often up to days), hypocomplementemia (particularly low C1q, C3, and C4), and histological evidence of leukocytoclastic vasculitis on skin biopsy, while SLE is a systemic autoimmune disease with multiorgan involvement that can present with HUV as one of its manifestations 1, 2.

Hypocomplementemic Urticarial Vasculitis (HUV)

Key Distinguishing Features

Clinical presentation:

• Non-pruritic urticarial lesions that persist for days (not hours like ordinary urticaria), often leaving residual hyperpigmentation or bruising 1, 3
• Weals in ordinary urticaria last 2-24 hours; HUV lesions persist for days 1
• Associated systemic manifestations include arthralgia/arthritis (most common), angioedema, ocular inflammation (conjunctivitis, episcleritis, uveitis), and potentially severe organ involvement 2, 4, 5

Laboratory findings:

• Low complement levels: C3, C4, and particularly C1q 2, 4, 3
• Positive anti-C1q antibodies (found in 6/10 patients in one series) 4
• Positive ANA in most cases (9/10 patients) 4
• ANCA positivity possible (5/10 patients) 4

Histopathology:

• Skin biopsy is essential and shows leukocytoclastic vasculitis with neutrophilic infiltration, endothelial cell damage, perivascular fibrin deposition, and red cell extravasation 1, 3

Classification and Etiology

HUV can occur as:

1. Primary (idiopathic) forms:

   • Systemic HUVS (S-HUVS): severe manifestations including pulmonary hemorrhage and glomerulonephritis, often associated with DNASE1L3 deficiency 4
   • Non-systemic HUVS (NS-HUVS): milder disease 4

2. Secondary forms: most commonly associated with SLE, but can occur with other autoimmune conditions 2, 4, 3

Severe Complications Requiring Vigilance

Life-threatening manifestations include:

• Pulmonary involvement (hemorrhage, obstructive lung disease—worsened by smoking) 4, 5
• Glomerulonephritis progressing to end-stage renal disease 4, 5
• Acute laryngeal edema (can be fatal) 5, 6

Systemic Lupus Erythematosus (SLE)

SLE is a chronic systemic autoimmune disease characterized by immune complex-mediated inflammation affecting multiple organ systems, with a relapsing-remitting course 7.

Core Features

Clinical manifestations span:

• Skin disease (malar rash, discoid lesions, photosensitivity)
• Musculoskeletal involvement (arthritis, arthralgia)
• Renal disease (lupus nephritis—requires biopsy for classification)
• Hematological abnormalities (thrombocytopenia, leukopenia, hemolytic anemia)
• Neuropsychiatric manifestations
• Serositis (pleuritis, pericarditis)

Laboratory hallmarks:

• Positive ANA (highly sensitive)
• Anti-dsDNA and anti-Smith antibodies (more specific)
• Low complement levels (C3, C4) during active disease
• Positive antiphospholipid antibodies in some patients

The Critical Diagnostic Challenge: HUV vs. SLE

The distinction between primary HUV and SLE-associated HUV is exceptionally difficult and often impossible, as both conditions share overlapping clinical features, laboratory abnormalities, and pathophysiological mechanisms (immune complex-mediated injury) 5, 8, 6.

Key Diagnostic Considerations

When evaluating chronic urticaria resistant to antihistamines:

1. Measure complement levels (C3, C4, C1q) as screening—low C4 has high sensitivity for complement deficiency 1
2. Perform skin biopsy of persistent lesions (>24 hours duration) to confirm vasculitis 1, 3
3. Screen for systemic autoimmune disease with ANA, anti-dsDNA, anti-C1q antibodies, and complete vasculitis workup 1, 4
4. Assess for organ involvement: renal function/urinalysis, pulmonary function tests, ophthalmologic examination 4, 5

The Overlap Dilemma

Many patients diagnosed with HUV subsequently develop or already meet SLE classification criteria 5, 8. The question of whether HUV represents a distinct entity or "SLE in evolution" remains unresolved 8. In practical terms, patients with HUV require surveillance for SLE development and vice versa 2, 4, 8.

Treatment Approach

For HUV (primary or SLE-associated):

• Hydroxychloroquine is widely used (8/10 patients in one series) and effective for both conditions 7, 4, 3
• Antihistamines for NS-HUVS with mild disease 4
• Immunosuppression required for S-HUVS and SLE-associated HUV: corticosteroids, mycophenolate, azathioprine, or cyclophosphamide depending on severity and organ involvement 7, 4, 3
• Colchicine may provide benefit in some cases 2

For SLE management (per 2019 EULAR guidelines):

• Hydroxychloroquine is foundational therapy for all SLE patients unless contraindicated 7
• Minimize glucocorticoids to <7.5 mg/day prednisone equivalent for chronic maintenance 7
• Add immunosuppressive agents (methotrexate, azathioprine, mycophenolate) for inadequate response or to enable steroid tapering 7
• Belimumab for refractory disease despite standard therapy 7

Critical Pitfall

Do not dismiss persistent urticaria (>24 hours per lesion) as simple chronic urticaria—this presentation mandates evaluation for urticarial vasculitis and underlying systemic disease, particularly in patients with hypocomplementemia or positive autoantibodies 1, 2, 3.